25 LLC’s Intellia Therapeutics NTLA Stock Holding History

25 LLC’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-12	Closed	-$550	–	374
2023 Q2	$550	Buy	+12	New	+$487	﹤0.01%	452

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

25 LLC's NTLA Position: Q3 2023 in Review

25 LLC sold out of Intellia Therapeutics (NTLA) in Q3 2023, closing a stake of 12 shares — an estimated $550 sold.

25 LLC first reported a position in NTLA in Q2 2023 and held it in 1 quarter. The position peaked at $550 in Q2 2023. 284 funds tracked by Wall St. Rank hold NTLA as of Q3 2023.

25 LLC reported no remaining Intellia Therapeutics position as of Q3 2023 after selling out during the quarter.
25 LLC sold 12 Intellia Therapeutics shares in Q3 2023, an estimated $550.
25 LLC first reported a position in Intellia Therapeutics in Q2 2023 and held it in 1 quarter.
25 LLC's Intellia Therapeutics position peaked at $550 in Q2 2023.
284 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2023.

Based on 25 LLC's 13F filing for Q3 2023, filed 18 Oct 2023.